Antibiotics Market size was valued at USD 50.55 billion in 2024 and is expected to cross USD 142.07 billion by the end of 2037, expanding at more than 8.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of antibiotics is estimated at USD 53.91 billion.
The growth of the market is primarily attributed to the worldwide growing prevalence of various communicable diseases, such as TB, HIV, and others. As per the World Health Organization (WHO) statistics, in 2020, an estimated 1.5 million (UI 1.0 to 2.0 million) people were infected with HIV for the first time. This brought the global HIV population to 38.4 million people by 2021.
Antibiotics are antibacterial compounds that are active against bacteria. It is the most common type of antibacterial agent used to treat bacterial infections. Antibiotic medications are commonly used to treat and prevent such infections. They either kill or inhibit bacterial growth. Such factor is leading up the growing consumption of various types of antibiotics across the globe. For instance, global antibiotic consumption rates surged by 47% between 2000 and 2018 (from 9.8 to 14.3 defined daily doses (DDD) per 1000 people per day).
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.2% |
|
Market Size in Base Year (2024) |
USD 50.55 billion |
|
Market Size in Forecast Year (2037) |
USD 142.07 billion |
|
Regional Scope |
|
Indication (Skin Infections, Respiratory, Gastrointestinal, UTIs, Blood Stream, Clostridium Difficile, Ear Infections)
The global antibiotics market is segmented and analyzed for demand and supply by indication into skin infections, respiratory, gastrointestinal, UTIs, blood stream, clostridium difficile, ear infections, and others. Out of these, the gastrointestinal segment is projected to significantly grow over the forecast period on the back of increasing prevalence of acute infectious diarrhea in children across the globe. For instance, acute infectious diarrhea is one of the most serious conditions in the world and is accountable for 1 million to 2.5 million deaths per year. Globally, more than 2 to 5 billion kids are affected every year.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Drug Origin |
|
|
By Spectrum of Activity |
|
|
By Indication |
|
|
By End-User |
|
APAC Market Statistics
The Asia Pacific antibiotics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. It is backed by the growing prevalence of infectious diseases, increasing consumption of antibiotics by regional population, significantly growing population, and growing healthcare expenditure in the region. For instance, around 4.2 billion people, or 61% of the world's population, reside in the Asia Pacific region.
GlaxoSmithKline plc and Spero Therapeutics have announced an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic that is anticipated to be used to treat complex urinary tract infections. Its 3rd phase clinical trial is estimated to start in 2023.
Teva Pharmaceuticals Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets as a therapeutic equivalent to Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. A variety of bacterial infections and rheumatic fever attacks are projected to be treated with these tablets in patients allergic to penicillin.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?